Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Common Equity (2016 - 2025)

Historic Common Equity for Veracyte (VCYT) over the last 14 years, with Q3 2025 value amounting to $1.3 billion.

  • Veracyte's Common Equity rose 694.07% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 694.07%. This contributed to the annual value of $1.2 billion for FY2024, which is 1262.94% up from last year.
  • According to the latest figures from Q3 2025, Veracyte's Common Equity is $1.3 billion, which was up 694.07% from $1.2 billion recorded in Q2 2025.
  • In the past 5 years, Veracyte's Common Equity registered a high of $1.3 billion during Q3 2025, and its lowest value of $971.2 million during Q2 2021.
  • Moreover, its 5-year median value for Common Equity was $1.1 billion (2022), whereas its average is $1.1 billion.
  • Per our database at Business Quant, Veracyte's Common Equity soared by 32944.5% in 2021 and then crashed by 532.06% in 2022.
  • Over the past 5 years, Veracyte's Common Equity (Quarter) stood at $1.1 billion in 2021, then dropped by 1.94% to $1.1 billion in 2022, then dropped by 2.89% to $1.0 billion in 2023, then rose by 12.63% to $1.2 billion in 2024, then rose by 6.95% to $1.3 billion in 2025.
  • Its Common Equity stands at $1.3 billion for Q3 2025, versus $1.2 billion for Q2 2025 and $1.2 billion for Q1 2025.